» Articles » PMID: 12472522

Prognostic Indicators for Malignant Tumours of the Parotid Gland

Overview
Date 2002 Dec 11
PMID 12472522
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The best treatment of malignant parotid tumours still remains to be defined, and a better knowledge about the tumour features that predict the treatment result is needed. The histological classification of parotid tumours may present difficulties on account of their great morphological diversity. In a series of 152 patients with a malignant tumour of the parotid gland, the prognostic factors and treatment results were investigated over a 25-year period. Treatment consisted of surgery, radiation therapy or a combination (49%, 13% and 38% respectively). Crude 5-year survival was 50% with significant differences related to stage (stage I, 65%; stage II, 50%; stage III, 21%; and stage IV, 9%). With respect to histopathology, the adenoid cystic carcinomas and the acinic cell carcinomas had the best prognosis (76% and 67% 5-year crude survival and 53% and 67% 10-year crude survival respectively). There was a significant difference in crude survival between well/intermediate and poorly differentiated tumours (P = 0.007). In a Cox hazard regression analysis including 136 patients and using death from cancer as the end-point, the following parameters were independent prognostic predictors: T-classification (P = 0.002), M-classification (P < 0.0001), N-classification (N+versus N0) (P = 0.005), local invasion (P = 0.003) and histological differentiation of the tumour (P = 0.03). The TNM system is a good predictor of treatment outcome for malignant parotid tumours. The use of a combination of clinical and histological factors will assist the design of treatment strategies for parotid gland tumours.

Citing Articles

Prognostic risk factor of major salivary gland carcinomas and survival prediction model based on random survival forests.

Chen Y, Li G, Jiang W, Nie R, Deng H, Chen Y Cancer Med. 2023; 12(9):10899-10907.

PMID: 36934429 PMC: 10225223. DOI: 10.1002/cam4.5801.


Clinico-Epidemiological Analysis of Most Prevalent Parotid Gland Carcinomas in Poland over a 20-Year Period.

Zurek M, Jasak K, Jaros K, Daniel P, Niemczyk K, Rzepakowska A Int J Environ Res Public Health. 2022; 19(16).

PMID: 36011881 PMC: 9408518. DOI: 10.3390/ijerph191610247.


Editorial for nomograms-based prediction of overall and cancer-specific survivals for patients diagnosed with major salivary gland carcinoma.

Asarkar A, Chang B Ann Transl Med. 2022; 9(23):1709.

PMID: 35071403 PMC: 8743708. DOI: 10.21037/atm-2021-10.


Clinicopathological Behavior and Oncological Outcomes of Malignant Parotid Tumors in a Pakistani Population.

Faisal M, Abbas T, Adeel M, Khaleeq U, Anwer A, Malik K Cureus. 2018; 10(2):e2157.

PMID: 29637038 PMC: 5886734. DOI: 10.7759/cureus.2157.


Management of salivary gland carcinomas - a review.

Wang X, Luo Y, Li M, Yan H, Sun M, Fan T Oncotarget. 2016; 8(3):3946-3956.

PMID: 27992367 PMC: 5354805. DOI: 10.18632/oncotarget.13952.